Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis. Cyclooxygenase-2 inhibitors and somatostatin analogues were reported to inhibit tumour angiogenesis. The pilot randomized controlled trial was aimed to prospectively evaluate the protocol of TACE combined with celecoxib and lanreotide (TACE+C+L) in patients with unresectab...

Background and Aim: Early prediction of tumor response is paramount for identification treatment failure as well guidance future therapy. Higher stiffness has been associated with incomplete to TACE. We aimed study the association between 2D-Shear Wave Elastography(2D-SWE) value Methods: 57 patients were enrolled. 3 excluded. Baseline characteristics analysed. All underwent 2D-SWE measurement f...

Chemoembolization with lipiodol (TACE) improves survival of selected patients with unresectable hepatocellular carcinoma (HCC), but results in substantial toxicity. To improve treatment tolerance, we conducted this phase II study using doxorubicin-loaded beads (DC Beads®) delivered by selective transcatheter arterial chemoembolization (DEB-TACE). ...

TNF-alpha converting enzyme (TACE; ADAM17), a member of the ADAM (a disintegrin and metalloprotease) family of metalloproteases, has been shown to cleave a wide variety of cell surface proteins of immunological importance. Due to the broad expression of TACE and the early postnatal lethality of TACE-deficient mice, it has been difficult to assess the role of TACE in lymphocyte development. Inde...

Transcatheter arterial chemoembolization (TACE) is the standard of care for nonsurgical patients with preserved liver function with large or multinodular noninvasive hepatocellular carcinoma (HCC) confined to the liver. The administration of an anticancer-in-oil emulsion followed by embolic agents is the most popular TACE technique; however, the introduction of embolic, drug-eluting beads (DEB)...

T ransarterial chemoembolization (TACE) is the most commonly performed therapy for inoperable hepatocellular carcinoma (HCC), and a complete response after the initial TACE or during the treatment course is the most robust predictor of a favorable outcome.1 TACE loads hypoxic and chemotherapeutic stress on HCC, and surviving tumors frequently change to a sarcomatous appearance2 or show a mixed ...

BACKGROUND Tumor necrosis factor-alpha converting enzyme (TACE) has recently been identified as a metalloproteinase-disintegrin, which converts pro-tumor necrosis factor-alpha (TNF-alpha) to the mature form, and is an important mediator in the pathogenesis of CHF. AIMS In order to establish the importance of TACE in the regulation of TNF-alpha synthesis in peripheral blood mononuclear cells (...

BACKGROUND This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrho...

Neutrophilic inflammation is associated with chronic airway diseases. It has been observed that human neutrophil elastase (HNE), which is secreted by active neutrophils during inflammation, induces both mucin overproduction and goblet cell metaplasia. Several in vitro studies suggest that tumor necrosis factor-α converting enzyme (TACE) regulates the signaling axis that mediates HNE-induced muc...

To the Editor, We read with great interest the article by Sansonno et al. [1] on transarterial chemoembolization (TACE) plus sorafenib in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). The authors did not provide information on the HCV kinetics of patients receiving this treatment intervention because of the oncologic nature of the study. Hepatitis B virus (HBV) a...